Kratium (Diazepam)

Diazepam binds to a specific site on the GABA‑A receptor complex, enhancing the inhibitory effect of GABA by increasing chloride ion influx. This results in reduced neuronal firing, producing anxiolytic, anticonvulsant, muscle‑relaxant, and sedative‑hypnotic actions.

The appropriate dose of Kratium is individualized and determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here.

Safety data for diazepam during pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs potential risks to the fetus or infant, and it should be prescribed only after careful risk‑benefit assessment by a qualified health professional.

To request Kratium, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Kratium (diazepam) has a relatively long half‑life and high lipid solubility, offering prolonged therapeutic effects compared with shorter‑acting agents such as lorazepam. This can be advantageous for sustained seizure control but may increase the risk of accumulation and sedation in patients with hepatic impairment.

Kratium should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Kratium is supplied for parenteral use and can be administered intravenously, intramuscularly, or rectally, depending on the clinical situation and the prescriber’s judgment. The route is selected to achieve rapid onset of action for seizures or procedural sedation, or to provide muscle relaxation.

The most serious risks include respiratory depression, severe hypotension, and the development of physical dependence or withdrawal syndrome after prolonged use. Patients should be monitored closely for these events, especially when combined with other central nervous system depressants.

Kratium is contraindicated in individuals with known hypersensitivity to diazepam or other benzodiazepines, in patients with acute narrow‑angle glaucoma, and in those with severe respiratory insufficiency. Caution is also advised for patients with a history of substance misuse or severe hepatic impairment.